STERIS plc (STE) 株式分析

企業概要

STERIS plc is a global provider of infection prevention products and services, operating across the healthcare, life sciences, and sterilization technology sectors. The company serves a broad range of clients through three distinct business segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences, each targeting specific needs within the medical device and infection control markets. Operating within the healthcare industry, the firm focuses on delivering cleaning chemistries, sterility assurance solutions, and automated endoscope reprocessing systems to hospitals, clinics, and research institutions. With a market capitalization of $22.09B and annual revenue reaching $5.83B, STERIS plc maintains a substantial scale supported by a workforce of 17,787 employees. These valuation and revenue figures indicate that the company holds a significant position in the global medical device landscape, reflecting its established footprint and ability to generate substantial economic activity.

財務健全性

The company reported revenue of $5.83B for the trailing twelve months, generating net income of $708.52M and EBITDA of $1.57B. The substantial gap between the $5.83B revenue and the $708.52M net income reveals a cost structure where approximately 87.9% of revenue is consumed by operating expenses, including the costs of goods sold, research and development, and general administrative overhead. Free cash flow stood at $870.70M, which provides the company with significant financial flexibility to fund capital expenditures, pursue strategic acquisitions, or manage seasonal cash flow fluctuations without relying on external financing. The company's profitability is characterized by a gross margin of 44.3%, an operating margin of 18.5%, and a profit margin of 12.1%. The high gross margin indicates strong pricing power and efficient supply chain management, while the operating and profit margins reflect the operational leverage and overhead costs inherent in a global manufacturing and service business. Regarding liquidity and solvency, total cash reserves of $423.70M are contrasted against total debt of $2.05B, resulting in a debt-to-equity ratio of 28.65. This leverage profile suggests a capital structure that relies on debt financing to expand operations, though the high debt level relative to equity implies a need for consistent cash flow generation to service obligations. The current ratio of 2.48 indicates a robust short-term liquidity position, as the company holds current assets more than double its current liabilities, ensuring it can comfortably meet immediate financial obligations. Furthermore, the return on equity is 10.5% and the return on assets is 6.6%, metrics that reveal management's effectiveness in generating profits from shareholder capital and utilizing the company's asset base efficiently.

バリュエーション評価

Valuation metrics for STERIS plc show a trailing P/E ratio of 31.34 and a forward P/E of 20.31. The significant difference between these two figures implies that the market expects earnings to grow substantially in the future, as investors are willing to pay a lower multiple for anticipated future earnings compared to historical performance. The price-to-book ratio is 3.09, which indicates that the market values the company at a significant premium over its net asset value, reflecting intangible assets such as brand reputation, intellectual property, and customer contracts that are not fully captured on the balance sheet. Alternative valuation multiples include a price-to-sales ratio of 3.79 and an EV/EBITDA of 15.06, suggesting that the company is valued at a premium relative to both its sales revenue and its earnings before interest, taxes, depreciation, and amortization. The stock's price range over the last year has fluctuated between a 52-week low of $204.90 and a 52-week high of $269.44. Without the specific current share price, the exact percentage deviation from these levels cannot be calculated, but the range demonstrates the volatility experienced by the equity within the healthcare sector. The beta of 1.07 indicates that the stock's price volatility is slightly higher than the broader market, meaning it tends to move 7% more than the overall market index during periods of fluctuation.

Growth & Income

STERIS plc has demonstrated solid growth momentum with revenue increasing by 9.2% year-over-year and earnings growing by 12.1% year-over-year. The fact that earnings growth exceeds revenue growth implies that the company is benefiting from operating leverage, cost efficiencies, or a favorable product mix that allows net income to expand at a faster rate than top-line sales. As a dividend payer, the company offers a dividend yield of 1.1% with a payout ratio of 33.5%. This payout ratio is considered sustainable given the company's earnings growth, as retaining approximately two-thirds of earnings provides ample room for reinvestment while returning capital to shareholders. The combination of consistent revenue expansion, accelerating earnings growth, and a moderate yet reliable dividend yield creates a balanced profile for investors seeking both capital appreciation and income generation within the medical device sector.